Background. Abnormal lipid metabolism contributes to the pathogenesis of diabetes, but it is uncertain whether it plays a role in the development of diabetic nephropathy (DN). While rapamycin was shown to prevent DN development in streptozotocin (STZ)-induced diabetic rats in our previous studies, it is unknown if it intervenes with lipid metabolism. Methods. We divided the rats into four groups: normal control rats, rapamycin-treated normal rats, diabetic rats and rapamycin-treated DN rats. The apoptosis was evaluated by immunohistochemistry. The crude lipid and sphingolipid were extracted from rat renal cortex and analysed by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The expression of the three key enzymes in sphingolipid metabolism including serine palmitoyltransferase, acid sphingomyelinase and sphingomyelin synthase was measured by western blot and immunohistochemistry in rat renal cortex. Results. The level of apoptosis was increased in diabetic rats, and rapamycin treatment reduced apoptosis. STZ treatment significantly increased formation of many sphingolipids species through elevated de novo synthesis. These changes were inhibited by treatment with rapamycin. Conclusions. Accumulation of sphingolipids contributes to STZ-induced diabetes, and the therapeutic effect of rapamycin on diabetic nephropathy is partly through suppression of sphingolipid abnormality.
Introduction
Diabetic nephropathy (DN) is one of the most frequent causes of chronic renal dysfunction. The early abnormalities in the kidney detected after the onset of diabetes include expansion of the mesangium, overexpression and deposition of extracellular matrix proteins [1] . It was reported that diabetic glomerulopathy was comprised of an early, transient mesangial cell (MC) proliferation and subsequent hypertrophy of these cells that heralded the slow progression into glomerulosclerosis [2] . Many lipids not only serve as structural material to provide a physical barrier for cells and provide a platform (the so-called lipid raft) for membrane protein-protein interaction but have distinct cellular functions and play important roles in the development of DN. Sphingolipids, the second largest group of membrane lipids, are the major components of the lipid raft for membrane protein-protein interaction. Ceramide is in the centre of sphingolipid metabolism. It can be generated from simple molecules by de novo synthesis pathway or from the hydrolysis of more complex sphingolipid [3] , as shown in Figure 1 . Serine palmitoyltransferase (SPT) is the rate-limiting enzyme in the de novo synthesis pathway for ceramide, while acid sphingomyelinase (ASM) and sphingomyelin synthase (SMS) control the balance between ceramide and sphingomyelin. Accumulating evidence has shown that sphingolipids and their metabolites are involved in many important signal transduction pathways that regulate cell cycle arrest, apoptosis, proliferation and calcium homeostasis and contribute to cancer development, multidrug resistance, viral or bacterial infection processes and kidney injury [3, 4] . Recently, the role of sphingolipids and key enzymes of sphingolipid metabolism in diabetes have been recognized. It was found that gangliosides could induce the rat renal MC proliferation [5] . Streptozotocin (STZ)-induced diabetes is associated with elevated activities of neutral ceramidase and sphingosinekinase and increased accumulation of the pro-proliferative sphingolipid sphingosine-1-phosphate in glomeruli [6] . The activity and expression of neutral ceramidase were elevated in the diabetic glomeruli at 4 days after induction of diabetes, but were inhibited after 28 days of diabetes, and endogenous sphingolipids took part in the advanced glycation end-products-induced MC growth [7, 8] .
But systematic study of the different lipid metabolism under health and disease conditions became possible only after the advent of 'lipidomics', in which individual lipid species can be analysed simultaneously by mass spectrometry (MS). It can collect vast amounts of information regarding the changes of lipids in different conditions [3, [9] [10] [11] . Different MS techniques, including matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) MS and liquid chromatography-electrospray ionization (LC-ESI)-MS/MS, are crucial for lipidomic study [12, 13] .
Rapamycin, an immunosuppressive macrolide, binds to FK-binding protein 12. This complex then inhibits the mammalian target of rapamycin (mTOR) signalling pathway [8] . A previous study showed that rapamycin can attenuate compensatory renal hypertrophy after unilateral nephrectomy [14] . Another study indicated that low-dose rapamycin inhibits MC proliferation, collagen IV production and laminin synthesis [15] . The blockade of mTOR by low-dose rapamycin has a beneficial effect in DN [16] . Our group reported previously that rapamycin can reduce albuminuria, glomerular enlargement, glomerular basement membrane thickening and renal macrophage recruitment in STZ-induced diabetes [17] . Therefore, rapamycin can prevent the early renal structural changes and halt the early steps of the development of DN, but the mechanism needs further in-depth investigation.
Since sphingolipids play important roles at the MC proliferation and hypertrophy of DN, and rapamycin treatment can attenuate the proliferation and hypertrophy, in the present study, we investigated the changes of sphingolipids in renal cortex of STZ-induced diabetic rats using MALDI-TOF MS to identify the changes of sphingolipid metabolism in diabetes and the influence of rapamycin treatment.
Materials and methods

Animal
Experiments involving animals were conducted following the regulation of the Guide for the Care and Use of Laboratory Animals, Zhejiang University, according to the protocols that we reported before [17] . Eightweek-old male Sprague-Dawley rats (200-250 g body weight) were purchased from Zhejiang University Animal Center (Hangzhou, China) and housed under controlled environmental conditions (temperature 22°C, 12-h darkness period). Water was given ad libitum.
Rats were divided into four groups: normal control rats (NC, n = 6), rapamycin-treated normal rats (NC + RAPA, n = 6), diabetic rats (DN, n = 6) and rapamycin-treated DN rats (DN + RAPA, n = 6) at random by weight. Diabetes was induced by intraperitoneal injection of STZ (Sigma-Aldrich, Germany) at 60 mg/kg body weight in 0.1 mmol/L citrate buffer (pH 4.5) after 12 h of food deprivation. Three days after STZ administration and twice a week thereafter, the rats were weighted, and tail-vein blood glucose was examined. Rats with blood glucose levels >16.7 mmol/L were considered to have diabetes. Rapamycin (1 mg/kg) was administered daily by gavage starting 3 days after STZ injection.
After diabetes induction, rats were placed in metabolic cages for collection of 24-h urine specimens on day 0 and on day 30. Blood pressure was measured by tail-cuff method. Serum and urine creatinine levels were determined by standard methods using an autoanalyser (Hitachi 7600, Japan). Urinary albumin excretion was determined by immunoturbidimetry (Hitachi 7020).
After a follow-up of 4 weeks, rats were sacrificed and kidney tissue samples were processed and stored as needed.
Histological studies
Tissue sections of kidney, 3-4 μm thick, were made for paraffin embedding and subsequent staining with periodic acid-Schiff (PAS). All samples were evaluated by a pathologist who was blind to group assignment. Mean glomerular volume was evaluated in PAS sections.
The following antibodies were used in immunohistochemical staining: rabbit anti-cleaved caspase 3 monoclonal antibody (1:200, Cell Signaling, USA), rabbit anti-ASM polyclonal antibody (1:200, Santa Cruz, USA), mouse anti-SMS polyclonal antibody (1:100, Santa Cruz, USA) and rabbit anti-SPT (1:200, Santa Cruz, USA). The number of positive stained tubules was calculated in 10 consecutive high power (×400) fields in all biopsies and expressed as the average percentage of the positive stained tubules over the total tubules in the field.
Crude lipid extraction
Crude lipids were extracted according to the method described by Folch et al. [18] as following: frozen renal tissues were chopped and homogenized in chloroform/methanol (2:1) and finally diluted to 20 times the volume of the original tissue sample volume using chloroform/methanol (2:1). The extract was then mixed thoroughly with 0.2 volume of water, and the mixture was separated into two phases and used for further analysis.
Sphingolipid extraction
The extraction of sphingolipids was conducted as described before [19] . Briefly, 1 mL lipid-containing lower phase, described above, was dried by vacuum centrifugation in a centrifugal evaporator (Speed-Vac, Thermo savant, Holbrook, NY). Five hundred microlitres of methanol containing 0.1 M NaOH was added to each tube at 55°C for 1 h to hydrolyse glycerophospholipids. After neutralization with 100 μL methanol containing 1 M HCl, 500 μL hexane and one drop of water were added to each sample. The samples were then centrifuged again at 6500 rpm for 15 min, and the lower phase was dried in a centrifugal evaporator after the upper phase was removed. The residue was mixed with 0.8 mL theoretical upper phase (chloroform:methanol:water, 86:14:1, v/v/v) and 0.2 mL theoretical upper phase (chloroform:methanol:water, 3:48:47, v/v/v) for Folch partition and centrifuged at 6500 rpm for 15 min. The lower phase was evaporated in a centrifugal evaporator after removing the upper phase to discard the salt. The residue, considered the crude sphingolipid fraction, was stored at −70°C for MALDI-TOF MS analysis.
DE MALDI-TOF MS analysis
Each sample obtained from the above procedure was dissolved in 5 μL chloroform-methanol (v/v, 2:1), followed by the addition of 5 μL matrix solution [0.5 M 2,5-dihydroxybenzoic acid (Sigma) solution in ethylacetate containing 0.1% TFA] in a 0.5 mL EP tube. The tube was vortexed vigorously and then centrifuged in a microcentrifuge for 1 min. One microlitre of mixture was directly spotted onto the sample plate and rapidly dried under a moderate warm stream of air in order to remove the organic solvent within seconds. All samples were analysed using a 4700 MALDI-TOF/TOF Analyzer (Applied Biosystems, USA) with a 377 nm N 2 UV laser. The mass spectra of samples were obtained in positive ion mode. Mass/charge (m/z) ratio was measured in the reflector/delayed extraction mode with an accelerating voltage of 20 kV, grid voltage of 67% and delay time of 100 ns. L-threo-sphingosylphosphorylcholine (MW 464.0) was used to calibrate the instrument. Crude lipid spectra were acquired using a mass range from m/z 500 to 2000. Sphingolipid spectra were acquired using a mass range from m/z 500 to 1000.
Establishment of reference mass spectrum and relative quantification
Reference mass spectra (RMS) were established, and relative quantification was processed as described before [20] . For analysing sphingolipids, we use the RMS to deal with problems of inter-animal variation, as well as the problem associated with the poor quantification ability of MALDI-TOF MS. Only those peaks presented in at least five mass spectra from the same group were chosen and put into the RMS. It was found that in all the mass spectra obtained, peak 725.62, which corresponds to SM [d16:1C18:0+Na] + , always had the relative intensity of 100%, meaning it was the highest peak in the mass spectra. Thus, the relative intensities of other peaks were calculated by comparing to peak 725.62. Then the mean and standard deviation of the relative intensity of each peak were established for each sample, and the particular lipid giving rise to the peak was identified by comparing their validated masses in lipid mass spectrum analysis database (http://lipid.zju.edu.cn). All the comparisons were then conducted using these RMS.
Protein extraction and western blot
Renal cortexes were homogenized and centrifuged in lysis buffer (1% NP40, 10% glycerol, 50 mmol/L HEPES, 137 mmol/L NaCl, 1 mmol/L MgCl 2 , 1 mmol/L CaCl 2 , 2 mmol/L Na 3 NO 4 , 10 mmol/L Na 4 P 2 O 7 , 100 mmol/L NaF, 5 μg/mL aprotinin, 1 mmol/L PMSF and 1 μg/mL leupeptin) at 4°C. The protein concentration in the supernatant was measured with a BCA protein assay kit (Pierce, Rockford, USA). Fifty micrograms of protein from each sample was blotted by rabbit anti-ASM polyclonal antibody (Santa Cruz, USA) at 1:200 dilution, mouse anti-SMS (Santa Cruz, USA) polyclonal antibody at 1:100 dilution and rabbit anti-SPT (Santa Cruz, USA) at 1:200 dilution. The density of the corresponding bands was measured quantitatively using image analysis software Bandscan 5.0 and corrected by reference to the value of β-actin.
Statistical analysis
Each experiment was conducted at least three times. Statistical analysis was performed using a Student's t-test. A probability level of P < 0.05 was considered significant. Data are presented as mean ± S.D.
Results
Metabolic data and biochemical parameters
Functional parameters for the various groups of rats are shown in Table 1 . The kidney/body weight ratio, mean glomerular volume, urine volume in 24 h, urine protein in 24 h, creatinine clearance and blood glucose of STZinduced diabetes rats were significantly increased compared with normal control. Treatment with rapamycin had no significant effects on hyperglycaemia, polyuria or body weight loss induced by diabetes. However, rapamycin treatment significantly reduced the kidney/body weight ratio, mean glomerular volume and alleviated proteinuria of diabetic rats, which was consistent with our previous study [17] . The representative renal pathological pictures of different groups are shown in Figure 2 .
Rapamycin reduced apoptosis in diabetic kidney
It has been reported that apoptosis is involved in the development of diabetic nephrology [21] . Therefore, we tested whether apoptosis was influenced by rapamycin treatment. We conducted immunohistochemical staining for activated caspase 3. The results showed that activated caspase 3 was increased in the tubular interstitial regions in diabetic kidney ( Figure 3 , Table 2 ). Rapamycin treatment significantly reduced the number of caspase 3-positive cells. These data indicate that rapamycin can inhibit apoptosis in DN. Significantly different versus DN (P < 0.05).
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Crude lipid analysis of rat renal cortex
Since the above results and our previous study [17] showed that rapamycin treatment can reduce apoptosis and inflammation in diabetic kidney, and sphingolipids such as ceramides are important mediators in these biological processes, we hypothesized that the sphingolipid profile might change in diabetic nephrology and in re- Significantly different versus DN group (P < 0.05).
Fig. 4.
Representative MALDI-TOF mass spectra of crude lipids in renal cortex of different rats. NC, normal control rats; NC + rapamycin, normal control rats treated with rapamycin; DN, STZ-induced diabetes rats; DN + rapamycin, STZ-induced diabetes rats treated with rapamycin. Crude lipid was extracted from rat renal cortex and analysed by MALDI-TOF MS. In the MS profiles of all these renal cortexes, no significant differences were observed.
Evaluation of sphingolipid metabolism in renal cortex of rats 1497 sponse to rapamycin treatment. Thus, we used MALDI-TOF MS to investigate both the crude lipids and sphingolipids in normal control, rapamycin-treated control, diabetic kidney and rapamycin-treated diabetic kidney. The crude lipid MALDI-TOF MS profiles of renal cortexes from four groups were similar and no obvious differences were observed; the representative mass spectra of crude lipids are shown in Figure 4 . Based on the pattern shown in previous reports [22] [23] [24] , two major classes of phospholipids [phosphatidylcholines (PC), sphingomyelins (SM)] were identified. It was found that m/z ions corresponding to PC comprised the main ions in the spectra. 
Sphingolipid profile changes dramatically in STZ-induced diabetes rats
Since PCs comprise the majority of crude lipid, the existence and change of other phospholipid classes at lower concentrations might be masked when detected in MALDI-TOF positive ion mode [25, 26] . In order to detect sphingolipids in rat renal cortex extracts, it is necessary to separate sphingolipids from crude lipids. Therefore, crude lipids were treated by mild alkalization, and sphingolipids were extracted and analysed by MALDI-TOF MS. Reference mass spectra for sphingolipids in the rat renal cortexes of normal control, rapamycin treatment, STZ-induced diabetes and STZ-induced diabetes treated with rapamycin were established with 21 identified major peaks ( Figure 5 ). Three classes of sphingolipids, ceramide (Cer), sphingomyelin (SM) and ceramide monohexoside (CMH), were identified for these 21 for Cer, SM and CMH species, were assigned. The major ion assignments in the mass spectra are listed in Table 3 . As shown in Figures 5 and 6 and Table 3 , the composition of ceramide was dramatically changed in the renal cortex extracts of DN rats compared with NC rats. In diabetic kidney, we identified eight new species of ceramide, The expression of SPT is up-regulated in STZ-induced diabetes rats, but can be attenuated by rapamycin treatment
In order to investigate why sphingolipid profile changed greatly in DN and by rapamycin treatment, we examined Evaluation of sphingolipid metabolism in renal cortex of rats 1499 three key enzymes in the synthesis pathway for ceramide, including ASM, SMS and SPT. Immunohistochemical results showed that these three enzymes were mainly localized in the tubular interstitial region (Figure 7) . The positive cells were tubular epithelial cell and microvascular endothelial cell. There was no significant change in the number of ASM-and SMS-positive cells, but the percentage of SPT-positive cells was greatly increased in DN rats and such elevation was inhibited by rapamycin treatment (Table 2) . Western blot analysis also revealed that the expression of SPTwas significantly increased in the renal cortex of DN rats compared with NC rats and this increase was reversed by rapamycin treatment, whereas no significant change was found for the levels of ASM and SMS in renal cortex between different experimental groups ( Figure 8 ). These results suggest that during development of DN, ceramide profile changes as a result of an elevated expression of SPT, and rapamycin treatment can reverse this change through regulating SPT.
Discussion
STZ-induced DN showed some signs of early stage DN including hyperglycaemia, albuminuria, high ratio of kidney-to-body weight and high kidney filtration. While treatment with rapamycin had no effect on hyperglycaemia, it significantly decreased albuminuria and the ratio of kidney-to-body weight. The effect of rapamycin on proteinuria is consistent with our previous study [17] and the report by Lloberas et al. [16] . This is also in accordance with the inhibitory effect of rapamycin on proteinuria in chronic hyperfiltration and inflammatory model [27] . Our group previously showed that cell proliferation and macrophage recruitment were elevated in STZ-induced DN and such changes were reduced by rapamycin [17] . In this study, we further tested apoptosis, which is also an important process in the early stage of DN in this model [28] , and the effect of rapamycin treatment. The immunohistochemical results for activated caspase 3 indicated that apoptosis was increased in diabetic kidney. Rapamycin treatment significantly reduced apoptosis. The fact that apoptosis was elevated in STZ-induced DN and rapamycin inhibited it suggests that apoptosis was caused by the factors that sensitive to rapamycin. Our finding that ceramide increased greatly in diabetic kidney and decreased after rapamycin treatment and the long established relationship of ceramide and apoptosis indicate that ceramide is a good candidate. Reports from several groups showed that inhibition of ceramide generation by inhibition of de novo synthesis such as inhibiting SPT or ceramide synthase effectively reduces cell death caused by chemical hypoxia, hypoxia-reoxygenation and radiocontrast media in tubular epithelial cells in kidney [29] [30] [31] . Our results showed that the increased expression of SPT, which represents the increased de novo synthesis of ceramide, was located mainly in tubular epithelial cells and microvascular endothelial cells, where the apoptosis mainly occurred, supporting the idea that increased ceramide induced apoptosis in DN.
Besides ceramide formation, glucosylceramide generation was also induced in DN. This is consistent with the study from Zador et al. [32] that the increase of renal gangliosides GM 3 was found in diabetic rats. Our previous study showed that Akt/mTOR pathway was activated in DN and rapamycin treatment suppressed its activation [17] . Recently, Natoli et al. reported that glucosylceramide accumulated in kidneys of polycystic kidney disease mouse model and inhibition of such accumulation effectively block the disease by blocking the activation of Akt/ mTOR [33] . This gives us a clue that the increased glucosylceramide may also participate in regulating Akt/mTOR pathway in DN. And although rapamycin directly inhibits mTOR complex, its suppression on glucosylceramide may also contribute to Akt/mTOR inhibition. The relationship between Akt/mTOR and sphingolipids in DN and rapamycin treatment requires further study.
In conclusion, in STZ-induced DN rat model, we found increased apoptosis in tubular interstitial regions, and rapamycin treatment reduced it. Using the lipidomic strategy, we analysed the sphingolipid composition and found that ceramide increased through de novo synthesis, which was also reversed by rapamycin treatment in the same kind of cell apoptosis occurred in diabetic kidney. These results indicate that elevated de novo synthesis of ceramide and ceramide accumulation participate in apoptosis and thus development of DN, and can be inhibited by rapamycin treatment.
